2021
PCSK9 Inhibiting Monoclonal Antibodies
Ahmed Z, Juthani P, Lee M, Desai N. PCSK9 Inhibiting Monoclonal Antibodies. Stroke Revisited 2021, 125-133. DOI: 10.1007/978-981-16-3923-4_11.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Lipid-lowering medicationsSubset of patientsIschemic strokeLower PCSK9Low-density lipoprotein cholesterolConvertase subtilisin/kexin type 9Subtilisin/kexin type 9Monoclonal antibodiesCoenzyme A (HMG-CoA) reductase inhibitorsComponents of dyslipidemiaHigh-intensity statinsStroke risk reductionModifiable risk factorsHealthy lifestyle modificationsLDL-C levelsRisk of strokeStatin-induced myopathyTreatment of hyperlipidemiaA Reductase InhibitorsLifestyle modificationStatin useLipoprotein cholesterolPCSK9 inhibitorsStroke outcome
2008
Amelioration of Human Allograft Arterial Injury by Atorvastatin or Simvastatin Correlates With Reduction of Interferon-γ Production by Infiltrating T Cells
Yi T, Rao DA, Tang PC, Wang Y, Cuchara LA, Bothwell AL, Colangelo CM, Tellides G, Pober JS, Lorber MI. Amelioration of Human Allograft Arterial Injury by Atorvastatin or Simvastatin Correlates With Reduction of Interferon-γ Production by Infiltrating T Cells. Transplantation 2008, 86: 719-727. PMID: 18791454, PMCID: PMC2650813, DOI: 10.1097/tp.0b013e318183eefa.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsGraft arteriosclerosisIFN-gamma productionIFN-gammaT cellsAllogeneic human peripheral blood mononuclear cellsHuman leukocyte antigen-DR expressionHuman IFN-gammaEndothelial cellsCoenzyme A (HMG-CoA) reductase inhibitorsT cell alloresponsesT cell accumulationAllogeneic endothelial cellsLong-term outcomesBlood mononuclear cellsEffect of statinsInterferon-γ ProductionA Reductase InhibitorsAortic interposition graftsReplication-deficient adenovirusVascular endothelial cellsTransplant arteryHuman artery segmentsStatin administration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply